Pharmacyte Biotech Inc (PMCB) Return on Equity ROE from the first quarter 2026 to first quarter 2026 and annually, average high and low, overall ranking from Jul 31 2026 to Jul 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Pharmacyte Biotech Inc   (NASDAQ: PMCB)

Pharmacyte Biotech Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Pharmacyte Biotech Inc in the first quarter 2026?
Pharmacyte Biotech Inc recorded a cumulative net loss of $-16 million during 12 months ending in the first quarter 2026, resulting in a negative return on equity (ROE) of -44.19%.

Within the Biotechnology & Pharmaceuticals industry 50 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2026 from 3017 to 3244.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jul 31 2026)
I. Quarter		 (Apr 30 2026)
IV. Quarter		 (Jan 31 2026)
III. Quarter		 (Oct 31 2025)
II. Quarter		 (Jul 31 2025)
I. Quarter
Y / Y Equity Change -36.89 % -35.84 % 87.69 % -18.91 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -16 -20 -6 -10 -5
Return On Equity (TTM) -44.19 % -47.85 % -14.12 % -25.61 % -10.9 %
PMCB's Total Ranking # 3244 # 3017 # 2749 # 134 # 194
Equity (TTM) in Millions 28 33 52 35 44
Seq. Equity Change -17.38 % -35.84 % 47.27 % -19.17 % -15.99 %
Seq. Net Income Change - - - - -

Back to PMCB Management Effectiveness >> PMCB's 5 Years Annual ROE >> Compare PMCB ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 51
Sector # 439
Overall # 3244

Return On Equity Statistics
High Average Low
62.23 %
-175.85 %
-3265.79 %
(Apr 30 2025)   (Oct 31 2013)





PMCB Annual Return On Equity (Apr 30 2026)
2026		 (Apr 30 2025)
2025		 (Apr 30 2024)
2024		 (Apr 30 2023)
2023		 (Apr 30 2022)
2022
Total Equity in Millions 33 52 28 73 90
Y / Y Equity Change -35.84 % 87.69 % -61.97 % -19.16 % 1246.21 %
Net Income in Millions -19 27 -2 -4 -4
Y / Y Net Income Change - - - - -
Return On Equity -58.34 % 51.18 % -7.9 % -5.94 % -4.71 %

Back to PMCB Management Effectiveness >> PMCB's 5 Years Annual ROE >> Compare PMCB ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PMCB's' Return on Equity at Yahoo Finance
PMCB's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PMCB's Competitors
Subscribers only: Roe for Pharmacyte Biotech Inc 's Suppliers
Subscribers only: Return On Equity for PMCB's Customers




Companies with similar Return On Equity at Jul 31 2026, within Healthcare Sector ROE

Date modified: 2026-09-15T12:00:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.